Form 8-K - Current report:
SEC Accession No. 0001682852-24-000057
Filing Date
2024-11-07
Accepted
2024-11-07 06:33:51
Documents
15
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrna-20241107.htm   iXBRL 8-K 30500
2 EX-99.1 exhibit9912024q3pressrelea.htm EX-99.1 178034
  Complete submission text file 0001682852-24-000057.txt   380969

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrna-20241107.xsd EX-101.SCH 2042
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrna-20241107_def.xml EX-101.DEF 14787
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrna-20241107_lab.xml EX-101.LAB 26043
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrna-20241107_pre.xml EX-101.PRE 15429
17 EXTRACTED XBRL INSTANCE DOCUMENT mrna-20241107_htm.xml XML 2900
Mailing Address 325 BINNEY STREET CAMBRIDGE MA 02142
Business Address 325 BINNEY STREET CAMBRIDGE MA 02142 6177146500
Moderna, Inc. (Filer) CIK: 0001682852 (see all company filings)

EIN.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38753 | Film No.: 241433008
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)